Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




May
12
Today In Oncology
First Virtual Cancer Clinic to Receive ASCO Certified Status
Meta-Analysis Explores Impact of Ovarian Function Suppression on Breast Cancer Recurrence and Survival
B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic GVHD
FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo